FY2023 EPS Estimates for Asensus Surgical, Inc. Boosted by Analyst (NYSEAMERICAN:ASXC)

Asensus Surgical, Inc. (NYSEAMERICAN:ASXC – Get Rating) – Investment analysts at Cantor Fitzgerald upped their FY2023 earnings estimates for Asensus Surgical in a research note issued to investors on Monday, March 6th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($0.25) per share for the year, up from their previous forecast of ($0.26). The consensus estimate for Asensus Surgical’s current full-year earnings is ($0.27) per share.

Separately, HC Wainwright reduced their target price on Asensus Surgical from $3.00 to $2.00 and set a “buy” rating for the company in a research note on Monday.

Asensus Surgical Price Performance

Asensus Surgical stock opened at $0.64 on Thursday. The firm has a market capitalization of $152.04 million, a price-to-earnings ratio of -1.99 and a beta of 1.81. Asensus Surgical has a 52 week low of $0.28 and a 52 week high of $1.18. The firm has a fifty day simple moving average of $0.55.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ASXC. Virtu Financial LLC increased its stake in Asensus Surgical by 150.7% during the 4th quarter. Virtu Financial LLC now owns 109,083 shares of the company’s stock worth $38,000 after acquiring an additional 65,569 shares during the period. Renaissance Technologies LLC lifted its holdings in Asensus Surgical by 58.5% during the 4th quarter. Renaissance Technologies LLC now owns 152,473 shares of the company’s stock worth $53,000 after buying an additional 56,300 shares during the period. UBS Group AG lifted its holdings in Asensus Surgical by 74.0% during the 4th quarter. UBS Group AG now owns 565,658 shares of the company’s stock worth $198,000 after buying an additional 240,648 shares during the period. Vanguard Group Inc. lifted its holdings in Asensus Surgical by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 11,431,792 shares of the company’s stock worth $5,130,000 after buying an additional 575,904 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Asensus Surgical by 41.2% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 296,100 shares of the company’s stock worth $134,000 after buying an additional 86,400 shares during the period. 11.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Asensus Surgical

In other Asensus Surgical news, Director Andrea Biffi acquired 293,077 shares of Asensus Surgical stock in a transaction on Friday, March 3rd. The shares were bought at an average price of $0.71 per share, with a total value of $208,084.67. Following the completion of the purchase, the director now owns 492,815 shares in the company, valued at $349,898.65. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 1.50% of the stock is owned by insiders.

Asensus Surgical Company Profile

(Get Rating)

Asensus Surgical, Inc is a medical device company, which digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities like augmented intelligence, connectivity and robotics in laparoscopy, and addresses the current clinical, cognitive, and economic shortcomings in surgery.